Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
NCT03066947Phase 2Completed
- Sponsor
- BriaCell Therapeutics Corp.
- Start
- May 2017
- Primary completion
- Nov 2018
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of SV-BR-1-GM in breast cancer, sponsored by BriaCell Therapeutics Corp.. Started May 2017; status: completed.
02
Drugs
SV-BR-1-GM
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03066947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066947.